22 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
15 May 24
Results of Operations and Financial Condition
4:34pm
Results R&D expense for the first quarter of 2024 was $7.6 million, compared to $5.5 million for the first quarter of 2023. The increase in R&D expense … is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
5 Apr 24
Other Events
4:33pm
. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
29 Mar 24
Results of Operations and Financial Condition
8:35am
treatment related adverse events were observed. 2023 Financial Results R&D expense for 2023 was $23.8 million, compared to $18.1 million for 2022 … . The increase in R&D expense was primarily due to increased manufacturing and clinical trial expenses as Elicio initiated the AMPLIFY-7P Phase 1a study
8-K
EX-99.2
ELTX
Elicio Therapeutics Inc.
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
splenectomy Data cutoff 6-Sept-23 P P P P P P C P P P P P P P P C P P P P P C P C C Tumor Type D D D D D D D R R D D D D D D D R D R D D D R D D KRAS
8-K
EX-99.1
hok30t3w
9 Nov 23
Results of Operations and Financial Condition
4:41pm
8-K
EX-99.2
crbs1o6y09d3 jrd
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
k8g iwzac
11 Aug 23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides
11:42am
8-K
eaxp3kt7ue0 udy5
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
S-4/A
EX-10.32
d2qv v85vlet
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
EX-10.30
748jlj4q0g7ij7w6o
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
8-K
EX-99.1
5kq0nv
30 Mar 22
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
4:52pm
8-K
EX-99.1
tu7ptlmh1o84msotio
12 Nov 21
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
bb3eqb7uy4vcvqsh
12 Aug 21
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:10pm
10-K
hg4gl
30 Mar 21
Annual report
5:00pm